Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more
Fusion Antibodies PLC (FAB) - Total Liabilities
Latest total liabilities as of September 2025: GBX1.09 Million GBX
Based on the latest financial reports, Fusion Antibodies PLC (FAB) has total liabilities worth GBX1.09 Million GBX as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fusion Antibodies PLC - Total Liabilities Trend (2006–2025)
This chart illustrates how Fusion Antibodies PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fusion Antibodies PLC Competitors by Total Liabilities
The table below lists competitors of Fusion Antibodies PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rome Resources Plc
LSE:RMR
|
UK | GBX435.00K |
|
Sky Century Investment Inc
PINK:SKYI
|
USA | $427.44K |
|
ANGANG STEEL -H-
MU:GNV
|
Germany | €48.27 Billion |
|
BEC WORLD -F-
MU:BW7
|
Germany | €3.26 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Fusion Antibodies PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fusion Antibodies PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fusion Antibodies PLC (2006–2025)
The table below shows the annual total liabilities of Fusion Antibodies PLC from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | GBX654.00K | +4.31% |
| 2024-03-31 | GBX627.00K | -33.23% |
| 2023-03-31 | GBX939.00K | -23.72% |
| 2022-03-31 | GBX1.23 Million | +13.67% |
| 2021-03-31 | GBX1.08 Million | -11.81% |
| 2020-03-31 | GBX1.23 Million | +38.21% |
| 2019-03-31 | GBX888.53K | +40.24% |
| 2018-03-31 | GBX633.59K | +40.73% |
| 2017-03-31 | GBX450.22K | +9.43% |
| 2016-03-31 | GBX411.43K | +104.01% |
| 2015-03-31 | GBX201.67K | -32.23% |
| 2014-03-31 | GBX297.57K | +17.35% |
| 2013-03-31 | GBX253.56K | -42.76% |
| 2012-03-31 | GBX443.00K | +15.97% |
| 2011-03-31 | GBX382.00K | +25.25% |
| 2010-03-31 | GBX305.00K | -51.82% |
| 2009-03-31 | GBX633.00K | +37.01% |
| 2008-03-31 | GBX462.00K | +3.36% |
| 2007-03-31 | GBX447.00K | +54.14% |
| 2006-03-31 | GBX290.00K | -- |